Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Otonecine)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST002759 AN004482 Metabolic responses of normal rat kidneys to a high salt intake (Kidney cortex) Kidney cortex Rat Medical College of Wisconsin Area
ST002760 AN004483 Metabolic responses of normal rat kidneys to a high salt intake (Kidney outer medulla) Kidney outer medulla Rat Medical College of Wisconsin Area
ST002761 AN004487 Metabolic responses of normal rat kidneys to a high salt intake (Urine) Urine Rat Medical College of Wisconsin Area
ST003087 AN005048 Metabolome changes in embryonic CSF (Part 9) CSF Mouse Autism Boston Children's Hospital, Harvard Medical School a.u.
ST000148 AN000235 A549 13C-labeled Cell Study Epithelial cells Human Cancer University of Kentucky normalized corrected peak area
ST000142 AN000225 H1299 13C-labeled Cell Study Lung Human Cancer University of Kentucky Peak area
ST000291 AN000464 LC-MS Based Approaches to Investigate Metabolomic Differences in the Urine of Young Women after Drinking Cranberry Juice or Apple Juice Urine Human University of Florida Peak area
ST000292 AN000466 LC-MS Based Approaches to Investigate Metabolomic Differences in the Plasma of Young Women after Drinking Cranberry Juice or Apple Juice Blood Human University of Florida Peak area
ST000311 AN000494 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak area
ST000311 AN000495 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak area
ST000335 AN000540 Metabolomics of bovine uterine fluid at the onset of conceptus elongation Uterus Cow University of Florida Peak area
ST002066 AN003365 Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer Lung Mouse Cancer The Walter and Eliza Hall Institute of Medical Research peak height
ST002698 AN004372 Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites Infected Red Blood Cells Plasmodium berghei Malaria Peter Doherty Institute for Infection and Immunity peak height
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University peak height
ST003053 AN005007 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University peak height
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University peak height
ST000286 AN000454 Mouse skeletal myotube chronic low-frequency stimulation Myotubes Mouse University of Florida Peak height
ST000311 AN000496 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak height
ST000311 AN000497 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak height
ST000403 AN000643 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000414 AN000655 Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000539 AN000819 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University Peak height
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University Peak height
ST003565 AN005857 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University Peak height
ST000549 AN000837 Investigating large scale metabolomics in mice serum lacking insulin receptors and IGF-1 receptors Blood Mouse Diabetes Mayo Clinic Peak intensity
ST000567 AN000872 Large Scale HILIC Profiling of the Effects of Curcumin Supplementation of Older Adults: Relation to Vascular Function Blood Human Heart disease Mayo Clinic Peak intensity
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST002094 AN003420 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST002094 AN003421 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST002094 AN003422 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University relative intensity
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University Signal Intensity
  logo